文献速递眼底病与葡萄膜炎

雷珠单抗港式给药系统治疗新生血管性年龄相关性黄斑变性:随机2期Ladder临床试验结果

The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial.
PubMed 文献 · Ophthalmology · 2019-04-01

这项2期多中心随机活性对照试验评估了雷珠单抗港式给药系统(PDS)治疗新生血管性年龄相关性黄斑变性的安全性和疗效,220例患者随机接受PDS 10 mg/ml、40 mg/ml、100 mg/ml或每月玻璃体腔注射雷珠单抗0.5 mg。首次补充中位时间随剂量增加而延长,PDS 100 mg/ml组第9个月视力与解剖 outcomes与每月注射组相当,但雷珠单抗总治疗次数减少。

要点

  • PDS 10、40、100 mg/ml组首次补充中位时间分别为8.7、13.0、15.0个月。
  • 第9个月BCVA变化:PDS 10 mg/ml组−3.2字母,40 mg/ml组−0.5字母,100 mg/ml组+5.0字母,每月注射组+3.9字母。
  • 手术优化后术后玻璃体出血率为4.5%(7/157),其中1例事件分类为严重。

核心结论

  • 在2期Ladder试验中,PDS总体耐受良好,并在多个终点上显示剂量反应。
  • PDS 100 mg/ml组的视力与解剖 outcomes与每月玻璃体腔注射雷珠单抗0.5 mg相当,但雷珠单抗总治疗次数减少。
  • PDS有潜力在维持视力的同时减少新生血管性年龄相关性黄斑变性的治疗负担。

研究设计与样本

  • 2期、多中心、随机、活性治疗对照临床试验。
  • 纳入9个月内诊断为新生血管性年龄相关性黄斑变性、既往接受过2次或以上抗血管内皮生长因子玻璃体腔注射且对治疗有反应的患者。
  • 患者按3:3:3:2随机接受PDS填充雷珠单抗10 mg/ml、40 mg/ml、100 mg/ml或每月玻璃体腔注射雷珠单抗0.5 mg。
  • 主要分析人群为220例患者,PDS 10 mg/ml组58例、PDS 40 mg/ml组62例、PDS 100 mg/ml组59例、每月玻璃体腔注射雷珠单抗0.5 mg组41例。

主要发现

  • 首次植入物补充中位时间在PDS 10 mg/ml、40 mg/ml、100 mg/ml组分别为8.7、13.0、15.0个月。
  • 第9个月最佳矫正视力较基线调整后平均变化:PDS 10 mg/ml组−3.2早期治疗糖尿病视网膜病变研究(ETDRS)字母,PDS 40 mg/ml组−0.5 ETDRS字母,PDS 100 mg/ml组+5.0 ETDRS字母,每月玻璃体腔注射雷珠单抗0.5 mg组+3.9 ETDRS字母。
  • 第9个月中心凹厚度较基线调整后平均变化在PDS 100 mg/ml组与每月玻璃体腔注射雷珠单抗0.5 mg组相似。
  • 优化的PDS植入物插入和补充程序总体耐受良好。
  • 手术程序优化后,术后玻璃体出血率为4.5%(7/157;其中1例事件分类为严重)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To evaluate the safety and efficacy of the Port Delivery System with ranibizumab (PDS) for neovascular age-related macular degeneration (nAMD) treatment. DESIGN: Phase 2, multicenter, randomized, active treatment-controlled clinical trial. PARTICIPANTS: Patients diagnosed with nAMD within 9 months who had received 2 or more prior anti-vascular endothelial growth factor intravitreal injections and were responsive to treatment. METHODS: Patients were randomized 3:3:3:2 to receive the PDS filled with ranibizumab 10 mg/ml, 40 mg/ml, 100 mg/ml, or monthly intravitreal ranibizumab 0.5-mg injections. MAIN OUTCOME MEASURES: Time to first implant refill assessed when the last enrolled patient completed the month 9 visit (primary efficacy end point), improvement in best-corrected visual acuity (BCVA) and central foveal thickness (CFT), and safety. RESULTS: The primary analysis population was 220 patients, with 58, 62, 59, and 41 patients in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. Median time to first implant refill was 8.7, 13.0, and 15.0 months in the PDS 10-mg/ml, PDS 40-mg/ml, and PDS 100-mg/ml arms, respectively. At month 9, the adjusted mean BCVA change from baseline was ‒3.2 Early Treatment Diabetic Retinopathy Study (ETDRS) letters, ‒0.5 ETDRS letters, +5.0 ETDRS letters, and +3.9 ETDRS letters in the PDS 10-mg/ml, PDS 40-mg/ml, PDS 100-mg/ml, and monthly intravitreal ranibizumab 0.5-mg arms, respectively. At month 9, the adjusted mean CFT change from baseline was similar in the PDS 100-mg/ml and monthly intravitreal ranibizumab 0.5-mg arms. The optimized PDS implant insertion and refill procedures were generally well tolerated. After surgical procedure optimization, postoperative vitreous hemorrhage rate was 4.5% (7/157; 1 event classified as serious). There was no evidence of implant clogging. CONCLUSIONS: In the phase 2 Ladder trial, the PDS was generally well tolerated and demonstrated a dose response across multiple end points in patients with nAMD. The PDS 100-mg/ml arm showed visual and anatomic outcomes comparable with monthly intravitreal ranibizumab 0.5-mg injections but with a reduced total number of ranibizumab treatments. The PDS has the potential to reduce treatment burden in nAMD while maintaining vision.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Campochiaro PA, Marcus DM, Awh CC, et al. The Port Delivery System with Ranibizumab for Neovascular Age-Related Macular Degeneration: Results from the Randomized Phase 2 Ladder Clinical Trial. Ophthalmology. 2019. PMID: 30946888. doi:10.1016/j.ophtha.2019.03.036

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。